BURLINGTON, Mass., Feb. 10, 2011 (GLOBE NEWSWIRE) -- Palomar Medical Technologies, Inc. (Nasdaq:PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, today announced financial results for the fourth quarter and year ended December 31, 2010. Revenues for the quarter ended December 31, 2010 increased to $16.4 million, as compared to $16.3 million reported in the fourth quarter of 2009. Product and service revenues were $14.3 million, a 2 percent increase over the $14.0 million reported in the fourth quarter of 2009. Fourth quarter gross margin from product and service revenues was 61 percent, which was consistent with the fourth quarter of 2009. Loss before income taxes for the fourth quarter ended December 31, 2010 was $2.4 million, which included a $0.6 million patent litigation expense and a $1.0 million non-cash stock-based compensation expense. Loss before income taxes for the fourth quarter ended December 31, 2009 was $3.3 million, which included a $0.2 million patent litigation expense and a $4.5 million non-cash stock-based compensation expense. Approximately $3.5 million of the fourth quarter 2009 non-cash stock-based compensation expense was a one-time expense related to the granting of restricted stock awards. The Company reported net loss of $2.6 million, or $0.14 per share for the fourth quarter of 2010 and $8.5 million for the fourth quarter of 2009. The balance sheet continues to be strong with $103.0 million in cash, cash equivalents, short-term investments, and marketable securities with no borrowings.

Revenues for the year ended December 31, 2010 increased to $63.7 million, as compared to $60.6 million reported in 2009. Product and service revenues were $53.5 million, a 10 percent increase over the $48.8 million reported in 2009. For the year ended December 31, 2010, gross margin from product and service revenues was 62 percent compared to 58 percent reported in 2009. Loss before income taxes for the year ended December 31, 2010 was $8.5 million, which included a $3.5 million patent litigation expense and a $3.8 million non-cash stock-based compensation expense. Loss before income taxes for the year ended December 31, 2009 was $6.0 million, which included a $0.8 million patent litigation expense and a $7.1 million non-cash stock-based compensation expense. The Company reported net loss of $8.8 million, or $0.47 per share for the year ended December 31, 2010, and a net loss of $10.5 million, or $0.58 per share for the year ended December 31, 2009. 

If you liked this article you might like

Palomar Medical Technologies Inc. Stock Upgraded (PMTI)

Palomar Medical Technologies Inc. Stock Downgraded (PMTI)

Insiders Trading FURX, DSW, PMTI, CTL

Insiders Trading AKAM, CRI, PMTI, MSFT

8 Stocks Rising on Huge Volume